Zymogenetics will make Q2 results available August 5th, it will be their first full quarter selling Recothrom. In January, ZymoGenetics launched its first product, Recothrom, a synthetic protein to stop bleeding during surgery, and analysts expect it will generate between $18 million and $23 million in sales this year. Those numbers are below initial estimates but analysts say sales will rise as the product establishes itself in the market.
Zymogenetics have said " The selling process is a long one and could take six months or more to work through with each hospital. We're making progress and expect that work to pay off in the second half of the year."
It will be interesting to see how the figures stack-up.
No comments:
Post a Comment